About this site

About GLP-1 Services

GLP-1 Services is a price and value directory for compounded GLP-1 telehealth. It is a reader-supported editorial project from Generational Health™: some provider links are affiliate links, and we may earn a commission when you sign up, at no extra cost to you. We publish that plainly, apply one rubric to everyone, and show real trade-offs.

Advertising disclosure: GLP-1 Services is a reader-supported editorial project from Generational Health™. Some provider links are affiliate links; if you sign up through one, we may earn a commission at no additional cost to you. Compensation never changes a provider's score — ratings follow our published methodology.

Who runs this site

This site is a reader-supported editorial project from Generational Health. We built GLP-1 Services because the hardest thing to pin down when shopping for a GLP-1 program is the real monthly cost, and a directory that puts price first is genuinely useful. Some of the provider links here are affiliate links: if you sign up through one, we may earn a commission at no additional cost to you. Rather than hide that arrangement, we disclose it on every page, next to the ranking, and here.

Affiliate compensation is a real relationship, and pretending otherwise would itself be the problem. Our answer is process: a published rubric, the same weights and scoring for every provider, real downsides stated in plain language, and sourced figures a reader can check. Compensation never changes a provider's score. If the data changed and a different provider offered better value on a like-for-like plan, our own rubric would move it up the table.

What we cover, and what we do not

We score compounded GLP-1 telehealth programs on price and value. The current directory covers ten programs, including MaxLife, Mochi Health, TrimRx, Eden, Ivim Health, Henry Meds, Zealthy, Willow, Fella Health, and Emerge. Providers that have moved away from compounded medication toward branded, FDA-approved products with insurance navigation — such as Ro and Hims & Hers — are mentioned for context but are not ranked in the compounded table, because they are a different product on a different cost basis.

We are a publisher, not a pharmacy. The telehealth providers we review are not drug manufacturers or compounding pharmacies; compounding is performed by their licensed pharmacy partners. This site does not prescribe, dispense, or provide medical care, and nothing here is medical advice.

Editorial standards

Three rules govern everything we publish. First, real data only: we never invent prices, ratings, patients, reviews, or providers, and any value we cannot confirm appears as a bracketed placeholder rather than a guess. Second, sourced and dated: competitor figures are compiled from each provider's own published pages plus external review sites, labeled sourced June 2026, verify live, because this pricing moves quickly. Third, honest trade-offs: every provider, including MaxLife, gets real pros and real cons, and where MaxLife loses on a criterion, we say so.

Comparisons here are decision aids, not attacks. Where we note a provider's legal or regulatory situation, we describe it factually, neutrally, and with sources, and we flag that such matters change. We do not run this site as a link farm: it links within itself and out to the providers it reviews (affiliate links disclosed), and not into a web of other sites.

Our medical-review process

Because this content sits in a health category, a licensed medical reviewer reviews the claims on this site for accuracy. Clinical statements — for example, that compounded GLP-1 medications are not FDA-approved, or that trial averages should be framed as averages rather than promises — are checked against the cited sources before publishing. The named reviewer and credential appear in the byline on each page.

{{Medical Reviewer Name, Credential}} serves as medical reviewer. {{Reviewer bio: role, licensure, and relevant experience to confirm}} Our reviewer checks that efficacy figures are presented as clinical-trial averages with an individual-results-vary caveat, that compounded medication is described as not FDA-approved wherever it is named, and that no content promises a specific health outcome.

How we handle pricing data

Pricing is the core of this directory, so we treat it carefully. Provider prices come from each program's public pricing pages and pricing blogs, cross-checked against external review sites, then dated. We re-verify on a roughly monthly cadence and update the visible date when we do. Because many provider pages block automated checks, some numbers are verified by hand, and there can be lag between a provider's change and our update — so confirm live pricing on the provider's own site before you buy. The full sourcing and cadence detail is on our methodology page.

Corrections and contact

If you believe a figure is out of date or wrong, we want to fix it. {{Contact method for corrections to confirm — email or form}} Corrections to pricing or review data are made at the next scheduled review, or sooner for a material error, and the updated date is reflected on the page.

Compounded medication notice: Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. They are prepared by U.S.-licensed compounding pharmacies when a licensed provider determines treatment is appropriate. Compounded semaglutide is not Ozempic® or Wegovy®; compounded tirzepatide is not Mounjaro® or Zepbound®. GLP-1 Services is not affiliated with Novo Nordisk or Eli Lilly. This site is for information only and is not medical advice.